The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Updated outcomes of patients with metastatic non-clear cell renal cell carcinoma (mnccRCC) treated with first-line (1L) therapies: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).
 
Kosuke Takemura
Honoraria - Bristol-Myers Squibb; MSD; Ono Pharmaceutical; Takeda
Research Funding - Suzuki Foundation for Urological Medicine; Takeda
Travel, Accommodations, Expenses - ESMO
 
Jeffrey Graham
Honoraria - Ipsen; Janssen Oncology; Merck; Pfizer
Consulting or Advisory Role - AstraZeneca; EMD Serono; ipsen; Janssen Oncology; Merck
 
David Maj
No Relationships to Disclose
 
Martin Zarba
No Relationships to Disclose
 
Connor Wells
No Relationships to Disclose
 
Razane El Hajj Chehade
No Relationships to Disclose
 
Marc Eid
No Relationships to Disclose
 
Eddy Saad
Research Funding - Genentech/Roche (Inst); Oncohost
 
Renee Maria Saliby
Honoraria - MashupMD
 
Jae Lyun Lee
Stock and Other Ownership Interests - Amgen; Black Diamond Therapeutics; Innovent Biologics; Johnson & Johnson/Janssen; Karyopharm Therapeutics; Merck; Zymeworks
Honoraria - AstraZeneca; Bristol-Myers Squibb; MSD
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Daiichi Sankyo/Astra Zeneca; Merck; Novartis
Research Funding - Amgen (Inst); Arcus Biosciences (Inst); Arcus Biosciences (Inst); AstraZeneca/MedImmune (Inst); Bayer Schering Pharma (Inst); Bristol-Myers Squibb (Inst); Eutilex (Inst); GI Innovation (Inst); Janssen (Inst); LG Chem (Inst); Loxo/Lilly (Inst); Merck KGaA (Inst); MSD (Inst); Novartis (Inst); Oscotec (Inst); Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst)
 
Frede Donskov
No Relationships to Disclose
 
Benoit Beuselinck
Consulting or Advisory Role - AstraZeneca (Inst); Bristol-Myers-Squibb (Inst); IPSEN (Inst); Merck KGaA (Inst); Pfizer (Inst)
Speakers' Bureau - Bristol-Myers-Squibb (Inst); Bristol-Myers-Squibb (Inst); Ipsen (Inst); Merck (Inst); Pfizer (Inst)
Research Funding - Bristol-Myers-Squibb (Inst)
Travel, Accommodations, Expenses - Ipsen (Inst); Ipsen (Inst); Pfizer (Inst)
 
Evon Jude
No Relationships to Disclose
 
Rana McKay
Consulting or Advisory Role - Ambrx; Ambrx; Arcus Biosciences; Astellas Medivation; AstraZeneca; AVEO; Bayer; Blue Earth Diagnostics; Bristol-Myers Squibb; Calithera Biosciences; Caris Life Sciences; Dendreon; Esiai; Exelixis; Janssen; Lilly; Merck; Myovant Sciences; NeoMorph; Novartis; Pfizer; Sanofi; Seagen; Sorrento Therapeutics; Sumitomo Pharma Oncology; Telix Pharmaceuticals; Tempus; Vividion Therapeutics
Research Funding - Artera (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol Myers Squibb (Inst); Exelixis (Inst); Oncternal Therapeutics (Inst); Tempus (Inst)
 
Naveen Basappa
Stock and Other Ownership Interests - illumiSonics
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Eisai; Ipsen; Janssen; Merck; Pfizer; Seagen; Takeda
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; EMD Serono; Ipsen; Janssen; Merck; Pfizer; Seagen
Research Funding - Ipsen (Inst)
Travel, Accommodations, Expenses - Eisai; Ipsen; Johnson & Johnson/Janssen; Pfizer
 
Sumanta Pal
Speakers' Bureau - IntrinsiQ; MJH Life Sciences; Peerview
Travel, Accommodations, Expenses - crispr therapeutics; Exelixis; Ipsen
 
Camillo Porta
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Eisai; Exelixis; Genenta Science; Ipsen; Merck Serono; MSD
Speakers' Bureau - Bristol-Myers Squibb; Eisai; Ipsen; Lilly; MSD; MSD
Travel, Accommodations, Expenses - Ipsen; MSD
 
Neeraj Agarwal
Research Funding - Amgen (Inst); Arvinas (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celldex (Inst); crispr therapeutics (Inst); Eisai (Inst); Exelixis (Inst); Genentech (Inst); Gilead Sciences (Inst); Immunomedics (Inst); Janssen (Inst); Lilly (Inst); Merck (Inst); Nektar (Inst); ORIC Pharmaceuticals (Inst); ORIC Pharmaceuticals (Inst); Pfizer (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Exelixis; Pfizer
 
Toni Choueiri
Stock and Other Ownership Interests - Abalytics Oncology; Bicycle Therapeutics; Curesponse; Inndura; Osel; Pionyr; Precede Bio; Primium; Tempest Therapeutics
Honoraria - Alkermes; Analysis Group; Aravive; Arcus Biosciences; Arcus Biosciences; ASCO; AstraZeneca; Bayer; Bristol-Myers Squibb; Clinical Care Options; Eisai; EMD Serono; ESMO; Exelixis; Foundation Medicine; Gilead Sciences; Gilead Sciences; GlaxoSmithKline; Harborside Press; HiberCell; Infinity Pharmaceuticals; Ipsen; Janssen Oncology; Kanaph Therapeutics; Lancet Oncology; Lilly; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; NiKang Therapeutics; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Precede Bio; Prometheus; Roche/Genentech; Sanofi/Aventis; Scholar Rock; Tempest Therapeutics; The New England Journal of Medicine; UpToDate
Consulting or Advisory Role - alkermes; Analysis Group; Aravive; Arcus Biosciences; Arcus Biosciences; ASCO; AstraZeneca; Bayer; bicycle; Bicycle Therapeutics; Bristol-Myers Squibb; Clinical Care Options; Curesponse; Eisai; EMD Serono; ESMO; Exelixis; Foundation Medicine; Gilead Sciences; Gilead Sciences; GlaxoSmithKline; Harborside Press; Infinity Pharmaceuticals; Ipsen; Janssen Oncology; Kanaph Therapeutics; Lancet Oncology; Lilly; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; Neomorph; NiKang Therapeutics; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Precede Bio; Prometheus; Roche/Genentech; Sanofi/Aventis; Scholar Rock; Tempest Therapeutics; The New England Journal of Medicine; UpToDate
Research Funding - Agensys (Inst); Arcus Biosciences (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Eisai (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); Merck (Inst); NiKang Therapeutics (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Roche (Inst); Roche/Genentech (Inst); Seattle Genetics/Astellas (Inst); Takeda (Inst); TRACON Pharma (Inst)
Patents, Royalties, Other Intellectual Property - -International Patent Application No. PCT/US2018/058430, entitled “Biomarkers of Clinical Response and Benefit to Immune Checkpoint Inhibitor Therapy (Inst); ctDNA technologies; International Patent Application No. PCT/US2018/12209, entitled “PBRM1 Biomarkers Predictive of Anti-Immune Checkpoint Response (Inst)
Travel, Accommodations, Expenses - Alexion Pharmaceuticals; alligent; Analysis Group; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Clinical Care Options; Corvus Pharmaceuticals; Eisai; EMD Serono; ESMO; Exelixis; Foundation Medicine; GlaxoSmithKline; Harborside Press; HERON; Ipsen; Kidney Cancer Association; Lancet Oncology; Lilly; Lpath; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Prometheus; Roche/Genentech; Sanofi/Aventis; The New England Journal of Medicine; UpToDate
Other Relationship - Medical writing and editorial assistance support may have been funded by Communications companies funded by pharmaceutical companies such as ClinicalThinking, Health Interactions, Envision Pharma Group, Fishawack Group of Companies, Parexel
 
Daniel Heng
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Eisai; Ipsen; Janssen; Merck; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Exelixis (Inst); Ipsen (Inst); Novartis (Inst); Pfizer (Inst)